OneSource is strategically positioned – with the remarkable growth of GLP-1s and the Biosecure Act – to address the increasing demand for drug-device combinations and biologics drug substances and products. It comes from the merger of Stelis' Biologics CDMO, SteriScience's Complex Injectables, and Strides' Soft Gelatin businesses. The newly combined CDMO has five world-class facilities approved by major regulatory agencies, including the US FDA, EU, and TGA. OneSource can produce more than 100 million injectable doses including cartridges and pre-filled-syringes and 2.4 billion soft gelatin capsules. Its flagship site in Bangalore is one of the few globally capable of manufacturing both biologics drug substances and drug products on the same premises.

OneSource’s end-to-end offering across all its platforms was established in response to its customers’ need to streamline supply chains by consolidating their outsourcing partners. The three combined businesses, each serve over 50 global clients, and together reduce complexity, cost, and resources associated with managing multiple CDMO service providers.

OneSource is projected to achieve 32% revenue growth in 2025, with sales anticipated to reach $400 million (€366 million) by 2028. The company’s strong growth prospects are due to the increase of self-administration of drugs via auto-injectors, led by the success of GLP-1 medications. In addition, the Biosecure Act is continuing to drive significant interest as pharma partners look to increase supply chain diversity and security, and serves as a tailwind to the CDMO’s ambitious growth plans.

“Our vision is to blend the expertise of global CDMO giants with the agility and service levels of a challenger, all supported by our unwavering commitment to bring the most efficient and quality products to our partners," commented  Neeraj Sharma, CEO of OneSource. "As demand for innovative CDMO solutions grows, especially for complex therapies, we are well-positioned to accelerate drug development and manufacturing for our global partners.”

OneSource is currently undergoing regulatory approvals and, upon completion, will be listed on the India stock exchange.